Trial Profile
An Exploratory Study to Evaluate Changes in Hepatic Fat Following Multiple-Dose Administration of MK-4074 and Pioglitazone Hydrochloride
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 4074 (Primary) ; Pioglitazone
- Indications Fatty liver
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 12 May 2014 New trial record